TY - JOUR
T1 - International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement
AU - on behalf of the ISG-EHCV
AU - Zignego, Anna Linda
AU - Ramos-Casals, Manuel
AU - Ferri, Clodoveo
AU - Saadoun, David
AU - Arcaini, Luca
AU - Roccatello, Dario
AU - Antonelli, Alessandro
AU - Desbois, Anne Claire
AU - Comarmond, Cloe
AU - Gragnani, Laura
AU - Casato, Milvia
AU - Lamprecht, Peter
AU - Mangia, Alessandra
AU - Tzioufas, Athanasios G.
AU - Younossi, Zobair M.
AU - Cacoub, Patrice
N1 - Publisher Copyright:
© 2017 The Authors
Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2017/5
Y1 - 2017/5
N2 - Hepatitis C virus (HCV) is both hepatotrophic and lymphotropic virus that causes liver as well extrahepatic manifestations including cryoglobulinemic vasculitis, the most frequent and studied condition, lymphoma, and neurologic, cardiovascular, endocrine-metabolic or renal diseases. HCV-extrahepatic manifestations (HCV-EHMs) may severely affect the overall prognosis, while viral eradication significantly reduces non-liver related deaths. Different clinical manifestations may coexist in the same patient. Due to the variety of HCV clinical manifestations, a multidisciplinary approach along with appropriate therapeutic strategies are required. In the era of interferon-free anti-HCV treatments, international recommendations for the therapeutic management of HCV-EHMs are needed. This implies the need to define the best criteria to use antivirals and/or other therapeutic approaches. The present recommendations, based on qualified expert experience and specific literature, will focus on etiological (antiviral) therapies and/or traditional pathogenetic treatments that still maintain their therapeutic utility.
AB - Hepatitis C virus (HCV) is both hepatotrophic and lymphotropic virus that causes liver as well extrahepatic manifestations including cryoglobulinemic vasculitis, the most frequent and studied condition, lymphoma, and neurologic, cardiovascular, endocrine-metabolic or renal diseases. HCV-extrahepatic manifestations (HCV-EHMs) may severely affect the overall prognosis, while viral eradication significantly reduces non-liver related deaths. Different clinical manifestations may coexist in the same patient. Due to the variety of HCV clinical manifestations, a multidisciplinary approach along with appropriate therapeutic strategies are required. In the era of interferon-free anti-HCV treatments, international recommendations for the therapeutic management of HCV-EHMs are needed. This implies the need to define the best criteria to use antivirals and/or other therapeutic approaches. The present recommendations, based on qualified expert experience and specific literature, will focus on etiological (antiviral) therapies and/or traditional pathogenetic treatments that still maintain their therapeutic utility.
UR - http://www.scopus.com/inward/record.url?scp=85016080037&partnerID=8YFLogxK
U2 - 10.1016/j.autrev.2017.03.004
DO - 10.1016/j.autrev.2017.03.004
M3 - Scientific review articles
C2 - 28286108
AN - SCOPUS:85016080037
SN - 1568-9972
VL - 16
SP - 523
EP - 541
JO - Autoimmunity Reviews
JF - Autoimmunity Reviews
IS - 5
ER -